Mononegavirales infectious disease
MONDO:0005856Infections with viruses of the order mononegavirales. The concept includes filoviridae infections; paramyxoviridae infections; and rhabdoviridae infections.
Also known as: Mononegavirales caused disease or disorder, Mononegavirales disease or disorder
207 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a booster RSV shot shield the immunocompromised?
⭐️ VACCINE ⭐️ Not yet recruitingThis phase 3 trial is investigating whether giving a repeat dose of the RSVpreF vaccine to immunocompromised adults is safe and triggers a strong immune response. Participants, aged 18 and older, will receive one shot and be monitored for about a year. The study aims to find the …
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 18, 2026 08:00 UTC
-
One shot, two viruses? new mRNA vaccine targets RSV and hMPV
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial tests an experimental mRNA vaccine called mRNA-1365 in healthy adults aged 60 and older. The vaccine is designed to trigger immunity against two respiratory viruses—RSV and hMPV—which can cause severe illness in older people. Researchers will evaluate the v…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Can a TB vaccine be upgraded to fight RSV in seniors?
⭐️ VACCINE ⭐️ Not yet recruitingThis trial is testing a new vaccine called rBCG-N-RSV, which is based on the BCG vaccine (used for tuberculosis) but modified to also target respiratory syncytial virus (RSV). The study involves 200 adults over 60 years old, who will receive either this new vaccine or the standar…
Phase: PHASE2 • Sponsor: Biothervax SpA • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial tests an experimental mRNA vaccine called YKYY025 designed to protect against respiratory syncytial virus (RSV). Healthy adults aged 18 and older receive a single injection of either the vaccine or a placebo. Researchers monitor safety, side effects, and im…
Phase: PHASE1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 12, 2026 00:00 UTC
-
Scientists test RSV vaccine to boost immune memory
⭐️ VACCINE ⭐️ Not yet recruitingThis study will test a new RSV vaccine in 60 adults aged 20 and older. Researchers want to understand how the vaccine triggers the immune system to create strong antibodies and memory T cells. The goal is to learn how to make RSV vaccines more effective.
Phase: NA • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new mRNA vaccine called IN006 to see if it is safe and helps the body fight RSV, a virus that can cause serious breathing problems. About 200 healthy adults, both younger (18-59) and older (60-79), will receive one or two shots of the vaccine or a placebo. Rese…
Phase: PHASE1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
New RSV vaccine trial aims to protect women from respiratory virus
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage study tests a new vaccine (MKK900) against respiratory syncytial virus (RSV) in 120 healthy women aged 18 to 49. The main goal is to check if the vaccine is safe and triggers a strong immune response. Participants will receive either the new vaccine or an active …
Phase: PHASE1 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Pregnancy shot may shield newborns from deadly RSV – major brazil trial launches
⭐️ VACCINE ⭐️ Not yet recruitingThis study will check how well a new RSV vaccine (RSVpreF) works when given to pregnant women in Brazil. Researchers will follow 5,000 infants up to 6 months old who are hospitalized or seen in clinics for respiratory illness. By comparing babies whose mothers got the vaccine to …
Sponsor: Inova Medical • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:09 UTC
-
New RSV mRNA vaccine enters first human safety tests
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial will test the safety of a new RSV mRNA vaccine in 60 healthy adults aged 18 and older. Participants will receive either a low dose, high dose, or a placebo (saline) shot. The study aims to see if the vaccine causes any side effects, paving the way for large…
Phase: PHASE1 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:05 UTC
-
RSV vaccine may shield babies born to mothers with HIV
Disease control Not yet recruitingThis study looks at whether the RSV vaccine given in late pregnancy can help protect babies born to mothers with HIV. RSV is a leading cause of infant hospitalization, and babies exposed to HIV are at higher risk. Researchers will measure antibody levels in mothers and infants to…
Phase: PHASE4 • Sponsor: University of British Columbia • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
Disease control Not yet recruitingThis study looks at the real-world effectiveness of the RSV vaccine Abrysvo in adults. Researchers will analyze health records from over 290,000 people to compare those who got the vaccine with those who did not. The goal is to see if the vaccine reduces hospitalizations and othe…
Sponsor: Pfizer • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a simple vaccine slash COPD attacks?
Disease control Not yet recruitingThis study tests whether a single dose of the RSV vaccine (Arexvy) can reduce moderate-to-severe COPD flare-ups in people who have frequent attacks. Researchers will enroll 320 high-risk patients aged 50+ and follow them for one year. Half will get the vaccine plus standard care,…
Phase: PHASE4 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can the RSV vaccine protect the most vulnerable? new study aims to find out
Disease control Not yet recruitingThis study tests whether the RSV vaccine Abrysvo can help blood cancer patients who have had a stem cell transplant or CAR-T therapy build immunity against RSV. Researchers will measure antibody levels before and after vaccination in 30 adults. The goal is to see if the vaccine t…
Phase: PHASE4 • Sponsor: The Cooper Health System • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New rapid ebola test could speed up outbreak detection
Diagnosis Not yet recruitingThis study evaluates a new diagnostic test called DECIPHER bioassay for detecting Ebola virus. Researchers will use stored blood and cheek swab samples from patients in the Democratic Republic of the Congo to see how well the new test compares to the standard lab method. The goal…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
New rapid tests aim to speed up ebola and lassa fever diagnosis
Diagnosis Not yet recruitingThis study evaluates two new diagnostic tests (FORTIFIEDx and DECIPHER) for detecting Ebola and Lassa viruses. Researchers will use stored blood and cheek swab samples from patients in Guinea to see how well these tests compare to the standard PCR method. The goal is to determine…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Could a single At-Home swab detect COVID, flu, and RSV?
Diagnosis Not yet recruitingThis study will test a new at-home diagnostic test that aims to detect five respiratory viruses—COVID-19, influenza A and B, RSV, and rhinovirus—from a single nose swab. About 2,000 people with cold or flu symptoms will provide samples in simulated home environments. The test's a…
Phase: NA • Sponsor: Aptitude Medical Systems • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
Can a new Four-in-One vaccine match the gold standard for childhood protection?
Prevention Not yet recruitingThis study tests an investigational vaccine that combines protection against measles, mumps, rubella, and chickenpox (varicella) in a single shot. It will be given as a second dose to healthy children aged 4 to 6 years who have already received a first dose of a similar vaccine. …
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
One shot to stop RSV: landmark trial for indigenous kids
Prevention Not yet recruitingThis study tests whether a single dose of nirsevimab, an antibody that targets RSV, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months. Around 1,000 children will be randomly assigned to receive either the antibody or standard care.…
Phase: PHASE4 • Sponsor: Menzies School of Health Research • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
New RSV shot for babies enters early human trials
Prevention Not yet recruitingThis study tests a new medicine called SIBP-A16 to see if it can safely prevent RSV in infants under 1 year old, including those born early. About 36 babies will receive either the new drug, a placebo, or an existing RSV drug. The main goal is to check for side effects and how th…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Could a vaccine and antibody combo stop ebola after exposure?
Prevention Not yet recruitingThis study tests whether giving the Ervebo Ebola vaccine together with the antibody drug Inmazeb still works to protect people who may have been exposed to Ebola. The vaccine alone takes time to work, while antibodies act fast but might interfere with the vaccine. Researchers wil…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Ebola breakthrough? new trial aims to stop virus after exposure
Prevention Not yet recruitingThis study tests whether giving a vaccine plus an antibody drug right after high-risk Ebola contact can prevent the disease better than the vaccine alone. About 160 people who have had close contact with an Ebola patient (like touching body fluids or a dead body) will be randomly…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Scottish data to reveal if RSV shot shields newborns
Knowledge-focused Not yet recruitingThis study looks at health records of babies born in Scotland to see if those whose mothers received the RSV vaccine (ABRYSVO) during pregnancy have fewer hospital visits for RSV. No new participants are enrolled; researchers will analyze existing data. The goal is to understand …
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New study tracks immune clues in seniors with flu, RSV, and COVID-19
Knowledge-focused Not yet recruitingThis study follows 150 adults aged 60 and older who have a respiratory infection (flu, RSV, or COVID-19) or who test negative. Researchers will measure specific immune markers in the blood over 60 days to see how they change from early infection to recovery. The goal is to better…
Sponsor: Fabiana Sherine Ganem dos Santos • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study aims to predict severe bronchiolitis in infants
Knowledge-focused Not yet recruitingThis study will observe 65 children, aged 1 to 24 months, hospitalized with bronchiolitis at Assiut University Hospital. Researchers will collect information on family, social, and medical factors to identify what makes the illness more severe. The goal is to help doctors predict…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Gut bacteria may predict severe RSV in kids
Knowledge-focused Not yet recruitingThis study looks at whether the types of bacteria in a child's gut can influence how sick they get from RSV, a common virus that can cause severe breathing problems in infants. Researchers in Vietnam will compare the gut bacteria and immune responses of 250 children with mild ver…
Sponsor: Phuc Huu Phan • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
New study to track RSV impact on turkish toddlers in ERs
Knowledge-focused Not yet recruitingThis study will observe up to 4,000 children under 5 years old who test positive for RSV and visit emergency departments in Turkey. Researchers will track how many children need to be admitted to the hospital or intensive care, and what treatments they receive. The goal is to bet…
Sponsor: Eskisehir Osmangazi University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Do childhood vaccines last? 5-year follow-up study launched in china
Knowledge-focused Not yet recruitingThis study follows 600 Chinese children who received standard vaccines against polio, measles, mumps, rubella, and hepatitis A. Researchers will test their blood to see if protective antibodies remain 5 years after vaccination. The goal is to understand how long vaccine protectio…
Sponsor: China National Biotec Group Company Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
10,000 adults to be tracked for RSV – could pave way for vaccine decisions
Knowledge-focused Not yet recruitingThis study will track 10,000 adults in Hong Kong with respiratory symptoms to measure how often RSV causes illness and how severe it gets. Researchers will collect nose and throat samples and blood tests over several weeks. The goal is to fill knowledge gaps about RSV in adults a…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Iron boost may make vaccines more effective in kenyan infants
Knowledge-focused Not yet recruitingThis study looks at whether giving iron to babies with low iron helps their bodies respond better to malaria and measles vaccines. About 324 infants in Kenya will take part. The goal is to see if treating iron deficiency can improve how well the vaccines protect them.
Phase: NA • Sponsor: Nicole Stoffel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Measles paradox: how a virus both wipes and boosts immune memory
Knowledge-focused Not yet recruitingThis study looks at 100 children to understand why measles causes short-term immune suppression but also lifelong immunity. Researchers will measure antibodies and immune cells before and after infection to see how measles changes the body's immune memory. The goal is to solve th…
Sponsor: Erasmus Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC